Determination of primary structure and microheterogeneity of a beta-amyloid plaque-specific antibody using high performance LC-tandem mass spectrometry

摘要

The amyloid beta-peptide (A(beta)) has a central role in initiating neurodegeneration in Alzheimer's disease (AD) and AD-related diseases (1,2), and has been an active target of a number of therapeutic approaches, including antibody immunotherapy. Therapeutically-active antibodies produced by active immunization with protofibrillar A(beta)(1-42) and fibrillar preparations have been found to reduce the amyloid burden and to improve cognitive functions in TgCRND8 transgenic mouse models of AD (3). The amino acid sequence and the glycosylation pattern of the 6E10 monoclonal antibody was determined using high performance LC-MS/MS.